Document:

EX-10.3 AMENDMENT TO EMPLOYMENT LETTER AGREEMENT

 

EXHIBIT 10.3

November 7, 2007

Mr. Stuart Grant

240 Summer Street

Norwell, MA 02061

RE: Amendment to Employment Letter Agreement for Stuart Grant Dated July 23, 2007.

Dear Mr. Grant:

     This letter amendment (the “Amendment”) effective as of the date above, will serve to amend the
letter agreement dated July 23, 2007 (the “Agreement”) regarding the terms and conditions of
your employment with BioCryst Pharmaceuticals, Inc. (the “Company”).

          1. Section 2(c) of the Agreement shall be deleted in its entirety and the following
paragraphs shall be substituted in lieu thereof:

          2(c) In addition to the basic compensation set forth in (a) and (b) above, Employee shall be
entitled to receive such other benefits and perquisites provided to other executive officers of
BioCryst which benefits may include, without limitation, reasonable vacation (currently 4 weeks),
sick leave, medical benefits, life insurance, and participation in profit sharing or retirement
plans.

Notwithstanding anything to the contrary contained herein, the Company and the Employee hereby
agree that in lieu of the standard executive relocation policy provisions, the Employee will
maintain his current home in the Boston area and secure an apartment in the Research Triangle Park
area and the Company agrees to provide the following travel perquisites for the Employee under the
terms set forth below:

               (i) Coverage of temporary living expenses for a period of three months beginning on
Employee’s initial start date with the Company;

               (ii) Flight expenses for coach class travel between Boston and Research Triangle Park for a
period of three months beginning from Employee’s initial employment with the Company;

               (iii) Shipment of selected goods from Boston to Employee’s Research Triangle Park
apartment, in such amounts as to be reasonably approved by Company;

               (iv) Flight expenses for coach class travel from Research Triangle Park to Boston on an every
other week basis during the initial three-year term of Employee’s contract, or until earlier
termination of the Agreement; and

               (v) Gross- up to cover taxes on the items listed above.

The parties further agree that the Company’s obligation with respect to total travel expenses set
forth in (iv) above shall not exceed $20,000.00 per year, with the first-year-period beginning on
July 23, 2007.

If at any time during the Employee’s employment with the Company as Chief Financial Officer, the
housing market improves such that Employee is able to sell his residence in the Boston area, then
upon agreement by both parties, Employee may relocate to the Research Triangle Park area and take
advantage of the executive relocation policy in effect as of the date hereof; provided, however,
that the total compensation paid to

 84

 

 

Employee under such executive relocation policy shall be reduced by the amount of total
compensation already paid to Employee in travel perquisites as set forth above.

          2. All other terms and conditions of the Agreement shall remain in full force and effect.

          3. The Agreement together with this Amendment constitutes the entire agreement between the
parties relating to the employment of the Employee by the Company and there are no terms relating
to such employment other than those contained in the Agreement, as amended by this Amendment.

[Signature Page to Follow]

 85

 

 

If the foregoing correctly sets forth our understanding, please signify your acceptance of such
terms by executing this Agreement, thereby signifying your assent, as indicated below.

Yours very truly,

/s/ Jon P. Stonehouse

Address:

2190 Parkway Lake Drive

Birmingham, Alabama 35244

AGREED AND ACCEPTED, as of this 7th day of November, 2007

/s/ Stuart Grant

Address:

240 Summer Street

Norwell, MA 02061EX-10.4 FORM OF NOTICE OF GRANT NON-EMPLOYEE

 

EXHIBIT 10.4

BIOCRYST PHARMACEUTICALS, INC.

STOCK INCENTIVE PLAN

NOTICE OF GRANT OF NON-EMPLOYEE DIRECTOR

AUTOMATIC STOCK OPTION

     Notice is hereby given of the following stock option grant (the “Option”) to purchase shares
of the Common Stock of BioCryst Pharmaceuticals, Inc. (the “Company”) pursuant to the automatic
grant program in effect under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (the “Plan”):

	 	 	 
	Optionee:

	 	                                    
                        
	 
	 	 
	Grant Date:

	 	                                     
                       
	 
	 	 
	Option Price:

	 	$                    per share
	 
	 	 
	Number of Optioned Shares:

	 	                    shares
	 
	 	 
	Expiration Date:

	 	                                     
                       
	 
	 	 
	Type of Option:

	 	Non-Statutory Stock Option
	 
	 	 
	Exercise Schedule:
	 	 

     Optionee understands that the Option is granted subject to and in accordance with the express
terms and conditions of the Plan and agrees to be bound by and conform to the terms and conditions
of the Plan, the Plan Prospectus, this Notice of Grant of Non-Employee Director Automatic Stock
Option and its accompanying Non-Employee Director Stock Option Agreement. Optionee acknowledges
that copies of the Plan, the Plan Prospectus, and the Non-Employee Director Stock Option Agreement
have been made available to Optionee.

     No Guarantee of Board Service: Nothing in the Non-Employee Director Stock Option
Agreement or the Plan shall confer upon the Optionee the right to continue in the Service of the
Company for any period of specific duration or interfere with or otherwise restrict in any way the
rights of the Company or the stockholders to remove Optionee from the Board in accordance with
applicable law.

     By my signature below, I hereby acknowledge receipt of this Option granted on the Grant Date
specified above and issued to me under the terms and conditions of the Plan.

	 	 	 	 	 	 	 	 	 	 	 
	Optionee:	 	 	 	 	 	BIOCRYST PHARMACEUTICALS, INC.	 	 
	 

	 	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Address:

	 	 	 	 	 	By:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Dated:

	 	 	 	 	 	Name:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 

87

 

BIOCRYST PHARMACEUTICALS, INC.

STOCK INCENTIVE PLAN

NON-EMPLOYEE DIRECTOR STOCK OPTION AGREEMENT

WITNESSETH:

RECITALS

          A. The Company has approved an automatic option grant program under the Company’s Stock
Incentive Plan (the “Plan”) pursuant to which the non-employee members of the Company’s Board of
Directors (the “Board“) will receive automatic option grants under the Plan.

          B. Optionee is a non-employee member of the Board, and this Agreement is executed pursuant to,
and is intended to carry out the purposes of, the Plan in connection with the automatic grant on
this day of a stock option to purchase shares of the Company’s Common Stock under the Plan.

          C. The granted option is intended to be a non-statutory option which does not meet the
requirements of Section 422 of the Internal Revenue Code and is designed to provide Optionee with a
meaningful incentive to serve as a member of the Board.

          NOW, THEREFORE, it is hereby agreed as follows:

          1. Grant of Option. Subject to and upon the terms and conditions set forth in this
Agreement, the Company hereby grants to Optionee, as of the grant date (the “Grant Date”) specified
in the accompanying Notice of Grant of Non-Employee Director Automatic Stock Option (the “Grant
Notice”), a stock option to purchase up to that number of shares of the Company’s Common Stock
(the “Optioned Shares”) specified in the Grant Notice. The Optioned Shares shall be
purchasable from time to time during the option term at the option price per share (the “Option
Price”) specified in the Grant Notice.

          2. Option Term. This automatic option grant shall expire at the close of business on
the Expiration Date specified in the Grant Notice (which shall be ten (10) years measured from the
Grant Date), unless sooner terminated in accordance with this Agreement.

          3. Limited Transferability. During the lifetime of the Optionee, this option (together
with its tandem stock appreciation right), shall be exercisable only by the Optionee and shall not
be assignable or transferable by the Optionee except for a transfer by will or by the laws of
descent and distribution following the Optionee’s death. Notwithstanding the foregoing, this
automatic option may, in connection with the Optionee’s estate plan, be assigned in whole or in
part during the during Optionee’s lifetime either as (i) as a gift to one or more members of
Optionee’s immediate family, to a trust in which Optionee and/or one or more such family members
hold more than fifty percent (50%) of the beneficial interest or an entity in which more than fifty
percent (50%) of the voting interests are owned by Optionee and/or one or more such family members,
or (ii) pursuant to a domestic relations order. The assigned portion shall be exercisable only by
the person or persons who acquire a proprietary interest in the option pursuant to such assignment.
The terms applicable to the assigned portion shall be the same as those in effect for this option
immediately prior to such assignment and shall be set forth in such documents issued to the
assignee as the Plan Administrator may deem appropriate.

          4. Exercisability. This option shall become exercisable for the Optioned Shares in
installments as is specified in the Grant Notice. As the option becomes exercisable for one or
more installments, the installments shall accumulate and the option shall remain exercisable for
the accumulated installments until the Expiration Date or the sooner termination of the option
term under this Agreement.

          5. Cessation of Board Service. Should Optionee cease to serve as a Board member for
any reason while holding this option, then Optionee shall have the remainder of the ten (10) year
term of this option in which to exercise such option for any or all of the Optioned Shares for
which it is exercisable at the time of such cessation of Board service. This option shall
immediately terminate and cease to be outstanding, at the time of such

 

 

\

cessation of Board service, with respect to Optioned Shares for which this Option is not
otherwise at that time exercisable. Upon the death of the Optionee, whether resulting in cessation
of Service or occurring thereafter, the personal representative of the Optionee’s estate or the
person or persons to whom this Option is transferred pursuant to the Optionee’s will or in
accordance with the laws of descent and distribution may exercise this Option for the remainder of
the ten (10) year term with respect to the Optioned Shares for which the Option was exercisable at
the time of Optionee’s death.

          6. Corporate Transaction.

               (a) In the event of one or more of the following transactions (a “Corporate
Transaction”):

                    (1) a merger or consolidation in which the Company is not the
surviving entity, except for a
transaction the principal purpose of which is to change the State of the Company’s incorporation,

                    (2) the sale, transfer or other disposition of all or
substantially all of the assets of the
Company in liquidation or dissolution of the Company, or

                    (3) any reverse merger in which the Company is the surviving
entity but in which securities
possessing more than fifty percent (50%) of the total combined voting power of the Company’s
outstanding securities are transferred to holders different from those who held such securities
immediately prior to such merger,

then the exercisability of this option (if outstanding at the time) shall automatically
accelerate so that such option shall, immediately prior to the specified effective date for the
Corporate Transaction, become fully exercisable for all of the Optioned Shares and may be exercised
for all or any portion of such shares.

               (b) This option, to the extent not previously exercised, shall terminate upon the consummation
of the Corporate Transaction and cease to be exercisable, unless it is expressly assumed by the
successor corporation or parent thereof. If so provided by the terms of the Corporate Transaction,
Optionee shall receive a cash payment on account of such termination of this option, in an amount
equal to the excess (if any) of (A) the Fair Market Value (as defined below) of the Optioned Shares
subject to this option as of the date of the Corporate Transaction, over (B) the Option Price for
such shares.

               (c) In the event of a Change in Control (as defined in the Plan), the exercisability of this
option (if outstanding at the time) shall automatically accelerate so that such option shall,
immediately prior to the specified effective date for the Change in Control, become fully
exercisable for all of the Optioned Shares and may be exercised for all or any portion of such
shares.

               (d) This Agreement shall not in any way affect the right of the Company to adjust, reclassify,
reorganize or otherwise make changes in its capital or business structure or to merge, consolidate,
dissolve, liquidate or sell or transfer all or any part of its business or assets.

          7. Adjustment in Optioned Shares.

               (a) In the event any change is made to the Common Stock issuable under the Plan by reason of
any stock split, stock dividend, recapitalization, combination of shares, exchange of shares, or
other change affecting the outstanding Common Stock as a class without receipt of consideration,
then appropriate adjustments shall be made to (i) the total number and/or class of Optioned Shares
subject to this option and (ii) the Option Price payable per share in order to reflect such change
and thereby preclude a dilution or enlargement of benefits hereunder.

               (b) If this option is to be assumed or is otherwise to remain outstanding after a Corporate
Transaction, then this option shall be appropriately adjusted to apply and pertain to the number
and class of securities which would have been issuable to the Optionee in the consummation of such
Corporate Transaction

89

 

had the option been exercised immediately prior to such Corporate Transaction, and appropriate
adjustments shall also be made to the Option Price payable per share, provided the aggregate Option
Price payable hereunder shall remain the same.

          8. Privilege of Stock Ownership. The holder of this option shall not have any
shareholder rights with respect to the Optioned Shares until such individual shall have exercised
the option and paid the Option Price.

          9. Manner of Exercising Option.

               (a) In order to exercise this option with respect to all or any part of the Optioned Shares
for which this option is at the time exercisable, Optionee (or in the case of exercise after
Optionee’s death, the Optionee’s executor, administrator, heir or legatee, as the case may be)
must take the following actions:

                    (1) Provide the Plan Administrator (or its designee) with written
notice of the option
exercise (the “Exercise Notice”) specifying the number of Optioned Shares for which the option is
being exercised.

                    (2) Pay the aggregate Option Price for the purchased shares in
one of the following
alternative forms:

                         (A) full payment in cash or check
payable to the Company’s order; or

                         (B) full payment in shares of
Common Stock held by Optionee for the requisite period necessary
to avoid a charge to the Company’s reported earnings and valued at Fair Market Value on the
Exercise Date; or

                         (C) full payment in a combination
of shares of Common Stock held for the requisite period
necessary to avoid a charge to the Company’s earnings and valued at Fair Market Value on the
Exercise Date and cash or check drawn to the Company’s order; or

                         (D) If the Company’s
outstanding Common Stock is registered under Section 12(g) of the
Securities Exchange Act of 1934, as amended (the “1934 Act”), at the time this option is exercised,
then payment of the Option Price may also be effected through a broker-dealer sale and remittance
procedure pursuant to which Optionee shall provide irrevocable written instructions (A) to a
designated brokerage firm to effect the immediate sale of the purchased shares and remit to the
Company, out of the sale proceeds available on the settlement date, an amount equal to the
aggregate Option Price payable for the purchased shares and (B) to the Company to deliver the
certificates for the purchased shares directly to such brokerage firm in order to complete the
sale.

                         (E) Furnish to the Company
appropriate documentation that the person or persons exercising the
option (if other than Optionee) have the right to exercise this option.

               (b) For purposes of subparagraph (a) above and for all other valuation purposes under this
Agreement, the Fair Market Value per share of Common Stock on any relevant date shall be determined
in accordance with the following provisions:

                    (1) If the Common Stock is not at the time listed or admitted to
trading on any national
securities exchange but is traded in the over-the-counter market, the Fair Market Value shall be
the mean between the highest bid and lowest asked prices (or, if such information is available, the
closing selling price) per share of Common Stock on the date in question in the over-the-counter
market, as such prices are reported by the National Association of Securities Dealers through the
Nasdaq system or any successor system. If there are no reported bid and asked prices (or closing
selling price) for the Common Stock on the date in question, then the mean

90

 

between the highest bid price and lowest asked price (or the closing selling price) on the
last preceding date for which such quotations exist shall be determinative of Fair Market Value.

                    (2) If the Common Stock is at the time listed or admitted to
trading on any national
securities exchange, then the Fair Market Value shall be the closing selling price per share of
Common Stock on the date in question on the securities exchange determined by the Plan
Administrator to be the primary market for the Common Stock, as such price is officially quoted in
the composite tape of transactions on such exchange. If there is no reported sale of Common Stock
on such exchange on the date in question, then the Fair Market Value shall be the closing selling
price on the exchange on the last preceding date for which such quotation exists.

                    (3) If the Common Stock is on the date in question neither listed
or admitted to trading on
any stock exchange nor traded in the over-the-counter market, then the fair market value shall be
determined by the Plan Administrator after taking into account such factors as the Plan
Administrator shall deem appropriate.

               (c) The Exercise Date shall be the date on which the Exercise Notice is delivered to the Plan
Administrator. Except to the extent the sale and remittance procedure specified above is utilized
for the exercise of the option, payment of the Option Price for the purchased shares must accompany
such notice.

               (d) As soon as practical after the Exercise Date, the Company shall issue to or on behalf of
Optionee (or other person or persons exercising this option) the purchased Optioned Shares via
electronic means or by delivery of a certificate or certificates representing the purchased
Optioned Shares.

               (e) In no event may this option be exercised for any fractional share.

          10. Compliance with Laws and Regulations.

               (a) The exercise of this option (or of its tandem stock appreciation right) and the issuance
of Common Stock hereunder shall be subject to compliance by the Company and Optionee with all
applicable requirements of law relating thereto and with all applicable regulations of any stock
exchange or over-the-counter market on which shares of the Company’s Common Stock may be listed or
traded at the time of such exercise and issuance.

               (b) In connection with the exercise of this option (or its tandem stock appreciation right),
Optionee shall execute and deliver to the Company such representations in writing as may be
requested by the Company in order for it to comply with the applicable requirements of Federal and
State securities laws.

          11. Successors and Assigns. Except to the extent otherwise provided in Paragraph 3,
the provisions of this Agreement shall inure to the benefit of, and be binding upon, the
successors, administrators, heirs, legal representatives and assigns of Optionee and the successors
and assigns of the Company.

          12. Liability of Company.

               (a) If the Optioned Shares covered by this Agreement exceed, as of the Grant Date, the number
of shares of Common Stock which may without shareholder approval be issued under the Plan, then
this option shall be void with respect to such excess shares unless shareholder approval of an
amendment sufficiently increasing the number of shares of Common Stock issuable under the Plan is
obtained in accordance with the provisions of the Plan.

               (b) The inability of the Company to obtain approval from any regulatory body having authority
deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant
to this Agreement shall relieve the Company of any liability with respect to the non-issuance or
sale of the Common Stock as to which such approval shall not have been obtained. The Company,
however, shall use its best efforts to obtain all such approvals.

91

 

          13. No Guarantee of Board Service. This Agreement shall in any way be construed or
interpreted so as to affect adversely or otherwise impair the right of the Company or the
stockholders to remove Optionee from the Board at any time in accordance with the provisions of
applicable law.

          14. Notices. Any notice required to be given or delivered to the Company under the
terms of this Agreement shall be in writing and addressed to the Company in care of the Corporate
Secretary at its principal corporate offices. Any notice required to be given or delivered to
Optionee shall be in writing and addressed to Optionee at the address indicated below Optionee’s
signature line on the Grant Notice. All notices shall be deemed to have been given or delivered
upon personal delivery or upon deposit in the U.S. mail, postage prepaid and properly addressed to
the party to be notified.

          15. Construction. This Agreement and the option evidenced hereby are made and granted
pursuant to the Plan and are in all respects limited by and subject to the express terms and
provisions of the Plan, including the automatic option grant provisions of the Plan.

          16. Governing Law. The interpretation, performance, and enforcement of this Agreement
shall be governed by the laws of the State of Alabama without resort to that State’s
conflict-of-laws rules.

          17. Tandem Stock Appreciation Right. Optionee is hereby granted a tandem stock
appreciation right, which entitles Optionee to surrender all or part of this option with respect to
Optioned Shares for which it is then vested and exercisable, for a distribution from the Company in
an amount equal to the excess of (A) the Fair Market Value (on the option surrender date) of the
Optioned Shares for which the option is surrendered, over (B) the Option Price for such Optioned
Shares. The distribution shall be made in shares of Common Stock valued at Fair Market Value on
the option surrender date. Any portion of this option that is surrendered in accordance with this
Paragraph shall cease to be outstanding and shall no longer be exercisable by Optionee.

92

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]